登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：300832 证券简称：新产业 公告编号：2025-068 一、重要提示 本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投 资者应当到证监会指定媒体仔细阅读半年度报告全文。 所有董事均已出席了审议本报告的董事会会议。 非标准审计意见提示 □适用 √不适用 董事会审议的报告期利润分配预案或公积金转增股本预案 □适用 √不适用 公司计划不派发现金红利，不送红股，不以公积金转增股本。 董事会决议通过的本报告期优先股利润分配预案 □适用 √不适用 公司是否需追溯调整或重述以前年度会计数据 □是 √否 ■ 3、公司股东数量及持股情况 单位：股 ■ 持股5%以上股东、前10名股东及前10名无限售流通股股东参与转融通业务出借股份情况 □适用 √不适用 前10名股东及前10名无限售流通股股东因转融通出借/归还原因导致较上期发生变化 控股股东报告期内变更 □适用 √不适用 公司报告期控股股东未发生变更。 实际控制人报告期内变更 □适用 √不适用 公司报告期实际控制人未发生变更。 □适用 √不适用 公司是否具有表决权差异安排 □ ...

Core Insights - The rapid development of artificial intelligence (AI) technology is driving a wave of transformation across various industries, with "black box laboratories" emerging as a key innovation in medical testing and drug development [1][2]. Group 1: Black Box Laboratories Overview - Black box laboratories, also known as smart or AI laboratories, operate 24/7 without human supervision, significantly enhancing research efficiency through automation and predictive modeling [2][3]. - The first AI-assisted automated laboratory was launched by Insilico Medicine in November 2024, demonstrating the practical application of black box laboratories in the pharmaceutical sector [2]. Group 2: Technological Innovations - Key innovations of black box laboratories include full-process automation and information integration, allowing seamless operation without human intervention, thus improving efficiency and accuracy [4][6]. - Advanced analytical techniques, such as simulated human eye visual recognition and intelligent peak recognition algorithms, contribute to the automation and intelligence of analytical instruments [5]. Group 3: Cost Reduction and Efficiency - Black box laboratories can reduce human labor costs by approximately 75% by replacing manual operations with intelligent systems, addressing issues of efficiency and data consistency in traditional laboratories [7][8]. - The automation process optimizes experimental steps and reduces overall operational costs by about 30%, enhancing the management efficiency of laboratories through real-time monitoring [8]. Group 4: Market Potential and Growth - The market for automated research laboratories in China has shown significant growth, increasing from 2.307 billion yuan in 2019 to 8.229 billion yuan in 2023, indicating high growth potential [10]. - Companies like Crystal Technology and BGI have reported substantial revenue growth in their automation business segments, with Crystal Technology's revenue from intelligent automation exceeding drug development revenue by 87.8% [10].

Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the analysis suggests a positive outlook based on revenue growth and market positioning. Core Insights - The company achieved a revenue of 4.535 billion yuan in 2024, representing a year-over-year growth of 15.41%. The net profit attributable to the parent company was 1.828 billion yuan, with a growth of 10.57% year-over-year [1][2] - The increase in the proportion of large machines has been a significant driver for both domestic and international business growth. In the domestic market, revenue reached 2.849 billion yuan, growing by 9.24% year-over-year, while international revenue was 1.686 billion yuan, with a substantial growth of 27.60% year-over-year [2] - The company is focusing on enhancing its product matrix and aims to become a comprehensive laboratory solution provider. Significant investments in R&D have been made to maintain a competitive edge in the high-end luminescence field [2] - The forecast for revenue from 2025 to 2027 is projected to be 5.163 billion yuan, 6.074 billion yuan, and 7.220 billion yuan, with corresponding year-over-year growth rates of 13.8%, 17.7%, and 18.9% respectively [2][3] Financial Summary - In 2024, the total revenue was 4.535 billion yuan, with a year-over-year growth rate of 15.4%. The net profit attributable to the parent company was 1.828 billion yuan, reflecting a growth rate of 10.6% [3] - The gross profit margin is expected to be around 70.4% in 2025, with a projected return on equity (ROE) of 21.2% [3] - Earnings per share (EPS) are forecasted to be 2.56 yuan in 2025, with a price-to-earnings (P/E) ratio of 20.46 [3]

Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the analysis suggests a positive outlook based on revenue growth and market positioning [1][2]. Core Insights - The company achieved a revenue of 4.535 billion yuan in 2024, representing a year-over-year growth of 15.41%, with a net profit of 1.828 billion yuan, up 10.57% year-over-year [1][2]. - The increase in the proportion of large machines has been a significant driver for both domestic and international business growth, with domestic revenue reaching 2.849 billion yuan (up 9.24% YoY) and international revenue at 1.686 billion yuan (up 27.60% YoY) [2]. - The company is focusing on enhancing its product matrix and R&D investments to solidify its position as a provider of comprehensive laboratory solutions, with notable advancements in high-end luminescence technology [2]. Financial Performance Summary - In 2024, the company reported total revenue of 45.35 billion yuan, with a net profit of 18.28 billion yuan and a net cash flow from operating activities of 13.56 billion yuan [1][3]. - The projected revenues for 2025, 2026, and 2027 are 51.63 billion yuan, 60.74 billion yuan, and 72.20 billion yuan, respectively, with corresponding net profits of 20.12 billion yuan, 24.29 billion yuan, and 30.28 billion yuan [2][3]. - The gross margin is expected to be around 70.4% in 2025, with a return on equity (ROE) of 21.2% [3].

Investment Rating - The report maintains a "Buy" rating for the company, indicating a strong expectation for future returns exceeding the market benchmark by more than 15% over the next 6-12 months [5][14]. Core Insights - The company achieved a revenue of 4.535 billion yuan in 2024, representing a year-on-year growth of 15.41%, and a net profit of 1.828 billion yuan, up 10.57% year-on-year [1][2]. - In Q1 2025, the company reported a revenue of 1.125 billion yuan, a 10.12% increase year-on-year, and a net profit of 438 million yuan, growing 2.65% year-on-year [1][2]. - The company has seen significant growth in its overseas market, with a revenue of 1.686 billion yuan in 2024, marking a 27.60% increase year-on-year [2][3]. - R&D investment reached 454 million yuan in 2024, up 23.92% year-on-year, supporting continuous innovation and product development [2][3]. Revenue and Profit Growth - The company’s revenue and profit have shown steady growth, with reagent income at 3.268 billion yuan (up 14.32%) and instrument income at 1.259 billion yuan (up 18.67%) in 2024 [2]. - The revenue growth rate is projected to be 14.27% in 2025 and 18.55% in 2026 and 2027 [4]. Market Expansion - The company has expanded its domestic market presence, reaching 1,732 tertiary hospital clients by the end of 2024, achieving a coverage rate of 44.93% [3]. - Internationally, the company has established operational systems in 14 core countries, enhancing its brand influence and driving regional growth [3]. Financial Projections - The EPS forecast for 2025 is adjusted to 2.54 yuan, with further projections of 3.11 yuan for 2026 and 3.73 yuan for 2027 [3][4]. - The current price corresponds to a P/E ratio of 21 for 2025, 17 for 2026, and 14 for 2027 [3][4]. Profitability and Valuation Metrics - The company’s gross margin is projected to be 72.1% in 2024, with a gradual decline to 69.4% by 2027 [12]. - The report indicates a consistent ROE, estimated at 21.32% for 2024 and expected to rise to 22.68% by 2027 [12].